Comparative Pharmacology
Head-to-head clinical analysis: ESTAZOLAM versus LIBERVANT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTAZOLAM versus LIBERVANT.
ESTAZOLAM vs LIBERVANT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and CNS depression.
GABA-A receptor positive allosteric modulator; enhances inhibitory neurotransmission.
1-2 mg orally at bedtime.
0.25 mg intravenously over 2 minutes, may repeat once after 15 minutes if inadequate response; maximum total dose 0.5 mg.
None Documented
None Documented
Terminal elimination half-life: 10-24 hours (mean ~17 hours); prolonged in elderly and hepatic impairment.
Clinical Note
moderateEstazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone propionate."
Clinical Note
moderateEstazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Estazolam."
Clinical Note
moderateEstazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Estazolam."
Clinical Note
moderateEstazolam + Cyclosporine
Terminal elimination half-life is approximately 2–4 hours in patients with normal renal function; may be prolonged up to 8–12 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~90% as metabolites, <1% unchanged. Fecal: small amount, ~10%.
Primarily renal excretion of unchanged drug (approximately 85%) and glucuronide conjugates (approximately 10%); biliary/fecal excretion accounts for less than 5%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Estazolam."